It inhibits both the kinase activity of FGFR1, FGFR2, and FGFR3 in FGFR-amplified breast cancer and the cellular activity of FGFR3 in t(4;14) multiple myeloma in pre-clinical studies [75, 76]. Here, FGFR2 is linked to breast carcinoma.